BKM120 in Metastatic Castration-resistant Prostate Cancer
Phase II Study of BKM120 in Men With Metastatic Castration-Resistant Prostate Cancer
調査の概要
詳細な説明
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
North Carolina
-
Durham、North Carolina、アメリカ、27710
- Duke Cancer Institute
-
-
Oregon
-
Portland、Oregon、アメリカ、97239
- OHSU Knight Cancer Institute
-
-
Washington
-
Seattle、Washington、アメリカ、98109
- University of Washington
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age ≥ 18 years
- Karnofsky performance status ≥ 70
- Life expectancy of ≥ 12 weeks as determined by treating investigator
- Adequate laboratory parameters
- Histologically confirmed diagnosis of adenocarcinoma of the prostate. Histologic variants of prostate cancer, including neuroendocrine features and small cell carcinoma of the prostate are permitted
- Radiographic evidence of metastatic disease
- Evidence of disease progression on androgen deprivation therapy (ADT)
- A minimum of 4 weeks elapsed off of antiandrogen therapy prior to registration (i.e. flutamide, nilutamide) and 6 weeks for bicalutamide, without evidence of an anti-androgen withdrawal response. Patients who did not have a PSA decline with the most recent antiandrogen therapy require only a 2 week washout period prior to registration
- A minimum of 2 weeks from prior abiraterone acetate, sipuleucel-T, MDV3100, orteronel (TAK700), ketoconazole, or other experimental anti-cancer therapies prior to registration is required. Concomitant treatment with enzalutamide is permitted.
- At least one prior systemic chemotherapy regimen FDA approved for metastatic prostate cancer
- A minimum of 4 weeks from any major surgery prior to registration
Exclusion Criteria:
- Have received prior treatment with a PI3K inhibitor
- Known hypersensitivity to BKM120 or to its excipients
- Untreated brain metastases
- Patients with hepatitis B or C, other acute or chronic liver disease, or a recent (within 12 months of administration of first dose of study drug) history of pancreatitis
- Patients with certain mood disorders as judged by the investigator or a psychiatrist
- History of treatment in an inpatient psychiatric setting
- Concurrent severe and/or uncontrolled cardiac conditions which could compromise participation in the study
- Other concurrent severe and/or uncontrolled concomitant medical conditions that could cause unacceptable safety risks or compromise compliance with the protocol
- Uncontrolled diabetes mellitus defined as a fasting plasma glucose level of >120.
- Diarrhea ≥ CTCAE grade 2
- Drugs or substances known to be strong inhibitors or inducers of the isoenzyme CYP3A4 should be avoided as systemic therapy in association with BKM120 as these can alter its metabolism. Topical use of creams or other applications not absorbed into the circulation is permitted
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BKM120 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
- Have been treated with any granulocyte colony-stimulating growth factors (e.g., G-CSF, GM-CSF) ≤ 2 weeks prior to starting study drug. Erythropoietin or darbepoetin therapy, if initiated at least 2 weeks prior to enrollment, may be continued
- Currently receiving treatment with medication that has the potential to significantly prolong the QT interval or induce Torsades de Pointes, and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug
- Have received immunosuppressive therapy including corticosteroids ≤ 2 weeks prior to starting study drug. Prednisone at a total daily dose of 10 mg orally or its equivalent is permitted, if initiated at least 2 weeks prior to enrollment
- History of solid organ or stem cell transplantation
- Have received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy prior to administration of first dose of study drug
- Have undergone major surgery ≤ 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy prior to administration of first dose of study drug
- Currently taking therapeutic doses of warfarin sodium or any other coumadin-derivative anticoagulant
- Known diagnosis of human immunodeficiency virus (HIV) infection
- History of another malignancy within 3 years, except cured basal cell or squamous cell carcinoma of the skin or low grade papillary bladder cancer Other inclusion and exclusion criteria apply
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:Study arm
BKM120 at 100mg orally daily
|
BKM120 at the maximum tolerated dose (MTD) of 100mg orally daily
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Progression Free Survival (PFS) Prostate Cancer Working Group 2 (PCWG2) Criteria or Based on the Onset of a Skeletal Related Event.
時間枠:5 years
|
Time in months from the start of study treatment to the date of first progression or death due to any cause. Progression was determined either radiographically using a composite of the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and Prostate Cancer Working Group 2 (PCWG2) criteria or clinically as judged from a skeletal-related event, need for change in therapy, or clinical deterioration. Patients alive who had not progressed as of the last follow-up had PFS censored at the last follow-up date. Median PFS was estimated using a Kaplan-Meier curve. Response and progression are evaluated using a combination of Response Evaluation Criteria in Solid Tumors (RECIST v1.1) and guidelines for prostate cancer endpoints developed by the Prostate Cancer Clinical Trials Working Group (PCWG2). Per RECIST, progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. |
5 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Radiologic Response
時間枠:2 years
|
The number of patients achieving a complete response (CR) or partial response (PR) based on RECIST 1.1 criteria.
Response and progression is evaluated using a combination of the Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1) and the guidelines for prostate cancer endpoints developed by the Prostate Cancer Clinical Trials Working Group (PCWG2).
Per RECIST, progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
|
2 years
|
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
時間枠:Up to 28 days post last study drug dose. This is the follow-up safety visit.
|
Number of patients experiencing grade 3-5 adverse events as defined by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
|
Up to 28 days post last study drug dose. This is the follow-up safety visit.
|
Prostate Specific Antigen (PSA) Response
時間枠:2 years
|
The number of patients with a 30% and 50% decrease in PSA from baseline.
|
2 years
|
Overall Survival of Participants.
時間枠:5 years
|
Time in months from the start of study treatment to date of death due to any cause.
Patients alive as of the last follow-up had OS censored at the last follow-up date.
Median OS was estimated using a Kaplan-Meier curve.
|
5 years
|
Change in Circulating Tumor Cell (CTC) Levels From Baseline
時間枠:2 years
|
The number of patients with a baseline CTC level of at least 5 who achieved a CTC level of less than 5 during the study.
|
2 years
|
Time to New Metastatic Disease From the Baseline Visit
時間枠:5 years
|
Time in days from the start of study treatment to time of new metastatic disease.
Time to new metastatic disease is, defined from the date of first study agent administration to the onset of a new evaluable site of disease as per PCWG2 and RECIST 1.1 guidelines, excluding the primary site and all sites documented at baseline will be assessed.
Only those patients that experienced a new lesion per this definition are included.
|
5 years
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Andrew Armstrong, MD, ScM、Duke Cancer Institute
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
前立腺がんの臨床試験
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); Highlight Therapeutics積極的、募集していない平滑筋肉腫 | 悪性末梢神経鞘腫瘍 | 滑膜肉腫 | 未分化多形肉腫 | 骨の未分化高悪性度多形肉腫 | 粘液線維肉腫 | II期の体幹および四肢の軟部肉腫 AJCC v8 | III期の体幹および四肢の軟部肉腫 AJCC v8 | IIIA 期の体幹および四肢の軟部肉腫 AJCC v8 | IIIB 期の体幹および四肢の軟部肉腫 AJCC v8 | 切除可能な軟部肉腫 | 多形性横紋筋肉腫 | 切除可能な脱分化型脂肪肉腫 | 切除可能な未分化多形肉腫 | 軟部組織線維肉腫 | 紡錘細胞肉腫 | ステージ I 後腹膜肉腫 AJCC (American Joint Committee on Cancer) v8 | 体幹および四肢の I 期軟部肉腫 AJCC v8 | ステージ... およびその他の条件アメリカ
BKM120の臨床試験
-
Novartis PharmaceuticalsNovartis引きこもった
-
Anne ChangNovartis Pharmaceuticals終了しました
-
Novartis Pharmaceuticals完了